Gene variant related to greater difficulty in quitting smoking and earlier lung cancer diagnosis

Science Spotlight

This is Archived Content. This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA). View current news releases on nida.nih.gov.

Blue smoke

People with a specific form of the CHRNA5 gene take an average of four years longer to quit smoking and are at greater risk for developing lung cancer four years earlier, compared to smokers without this gene variant. This is according to a meta-analysis of 24 studies examining variants in the CHRNA5 gene within participants of European ancestry. By some measures, approximately 18% of people with this ancestry carry the high-risk variant.

Although past analyses have shown a relationship between this gene variant and heavy smoking, this is the first meta-analysis to clarify the role of CHRNA5 variations in smoking cessation. This genetic marker may help improve early lung cancer detection in a high-risk population.

This analysis was funded by various NIH Institutes, including NIDA. For a copy of the article, published in the Journal of the National Cancer Institute, go to: http://jnci.oxfordjournals.org/content/107/5/djv100.full?sid=5170a62f-6259-48d0-a6b7-78dae2f03266

For more information, contact the NIDA press office at media@nida.nih.gov or 301-443-6245.